Steven Cohen Kodiak Sciences Inc. Transaction History

Point72 Asset Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.3 - $9.48 $68,077 - $150,087	-15,832 Reduced 99.78%	35 $0
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $76,320 - $140,898	15,867 New	15,867 $98,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.48 $2.73 Million - $5.13 Million	541,400 New	541,400 $4.14 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $417M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.